Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions

Journal of Medical Virology

Volumn 84, Issue 1, 2012, Pages 170-181

  Brooks, Megan J ^a,e   Burtseva, Elena I ^b   Ellery, Philip J ^c   Marsh, Glenn A ^a,f   Lew, Andrew M ^d   Slepushkin, Anatoly N ^b   Crowe, Suzanne M ^c   Tannock, Gregory A ^a,c  

^a RMIT UNIVERSITY   (Australia)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^c BURNET INSTITUTE   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f CSIRO   (Australia)

Author keywords

Antiviral; Broad spectrum; Conditions; Respiratory

Indexed keywords

ALPHA INTERFERON; AMANTADINE; ARBIDOL; HEMAGGLUTININ; RIMANTADINE; SIALIDASE; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; AVIAN INFECTIOUS BRONCHITIS VIRUS; DRUG ACTIVITY; ENZYME ACTIVITY; HUMAN; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS A H3N2; MARDIVIRUS; MESSENGER RNA SYNTHESIS; MOUSE; NONHUMAN; PARAMYXOVIRUS; POLIOMYELITIS VIRUS 1; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY VIRUS; VIRUS ENVELOPE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; INDOLES; LUNG; MALE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; ORTHOMYXOVIRIDAE INFECTIONS; RESPIRATORY TRACT INFECTIONS; VIRAL LOAD; VIRAL PLAQUE ASSAY; VIRUSES;

AVES; GALLID HERPESVIRUS 2; MUS; POLIOVIRUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 81355138347     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22234     Document Type: Article

References (47)

1. Anonymous. 2007. Guidance for industry, role of HIV resistance, testing in antiretroviral drug development. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD.
2. Besselaar TG, Naidoo D, Buys A, Gregory V, McAnerney J, Manamela JM, Blumberg L, Schoub BD. 2008. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg Infect Dis 14: 1809-1810.
3. Boriskin Y, Pecheur E, Polyak S. 2006. Arbidol: A broad-spectrum antiviral that inhibits acute and chronic HCV infection. Virol J 3: 56-62.
4. Browne M, Moss M, Boyd M. 1983. Comparative activity of amantadine and ribavirin against influenza virus in vitro: Possible clinical relevance. Antimicrob Agents Chemother 23: 503-505.
5. De Laney DB. 1999. The development of a serotype 1 vaccine against Marek's disease. Melbourne, Australia: Department of Biotechnology and Environmental Biology, RMIT University.
6. Diaz M, Zieman S, Le Beau M, Pitha P, Chilcote R, Rowley J. 1988. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci USA 85: 5259-5263.
7. Egorov A, Brandt S, Sereinig S, Romanova J, Ferko B, Katinger D, Grassauer A, Alexandrova G, Katinger H, Muster T. 1998. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol 72: 6437-6441.
8. Fadeeva NI, Leneva IA, Panisheva EK, Busse TL, Khristova ML, Kharitonenkov IG, Granik VG. 1992. Inhibitors of the early stages of virus-cell interactions among derivatives of 3-ethoxycarbonyl-5-hydroxy-6-bromoindole. Khimiko-Farmatsevticheskii Zhurnal 26: 17-20 (In Russian).
9. Fiszon B, Hannoun C. 1990. Comparison of neuraminidases of the same subtype but from different species using a new method of titration. J Virol Methods 27: 79-90.
10. Gagarinova VM, Ignat'eva GS, Sinitskaia LV, Ivanova AM, Rodina MA, Tur'eva AV. 1993. The new chemopreparation arbidol: Its prophylactic effectiveness during influenza epidemics. Zh Mikrobiol Epidemiol Immunobiol 5: 40-43 (In Russian).
11. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, Palese P, Muster T. 1998. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252: 324-330.
12. Glushkov RG. 1992. Arbidol. Drugs Future 17: 1079-1081.
13. Glushkov RG, Fadeeva NI, Leneva IA, Gerasina SF, Budanova LI, Sokolova ND, Stebaeva LF, Kuzovkin VA, Degtyarev EV, Sokolova TM, Fedyakina IT. 1992. Molecular biological characteristics of the action of arbidol-A new antiviral drug Khimiko-Farmatsevticheskii Zhurnal 26: 8-15 (In Russian).
14. Glushkov RG, Guskova TA, Krylova LY, Nikolayeva IS. 1999. The mechanisms of arbidol's immunomodulating action. Vestnik Rossiiskoi Akademii Meditsinskih Nauk 3: 36-40 (In Russian).
15. Gubareva LV, McCullers JA, Bethell RC, Webster RG. 1998. Characterisation of influenza A/Hong Kong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J Infect Dis 178: 1592-1596.
16. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. 1986. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother 18: 19-29.
17. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE. 1999. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment. JAMA 282: 1240-1246.
18. Helenius A. 2007. Chapter 4: Virus entry and uncoating. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, editors. Field's virology. 8th edition. Philadelphia: Lippincott, Williams and Wilkins.
19. Ison MG, Gubereva LV, Atmar RL, Treanor JJ, Hayden FG. 2006. Recovery of drug-resistant influenza virus from immunocompromised patients: A case series. J Infect Dis 193: 760-764.
20. Kim C, Lew W, Williams M, Zhang L, Liu H, Swaminathan S, Bischofberger N, Chen M, Tai C, Mendel D, Laver W, Stevens R. 1997. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119: 681-690.
21. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. 2004. Resistant influenza viruses in children treated with oseltamivir: A descriptive study. Lancet 364: 759-765.
22. Leneva IA, Fadeeva NI, Fedyakina IT, Guskova TA, Khristova ML, Sukolova MV, Kharitonenkov IG. 1994. Use of enzyme immunoassay to identify virus-specific antigens in studying a new anti-influenza preparation, arbidol. Khimiko-Farmatsevticheskii Zhurnal 28: 605-610 (In Russian).
23. Leneva IA, Hay AJ. 1998. The mechanism of action of arbidol against influenza virus: Selection and characterisation of arbidol-resistant mutants, Abstract. 11th International Conference on Antiviral Research, Abstract 177, San Diego, CA.
24. Leneva IA, Russell RJ, Boriskin YS, Hay AJ. 2009. Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol. Antiviral Res 81: 132-140.
25. Leneva IA, Sokolova MV, Fediakina IT, Khristova ML, Fadeeva NI, Guskova TA. 2002. Study of the effect of antiviral drugs on the reproduction of respiratory syncytial virus by enzyme immunoassay. Vopr Virusol 47: 42-45 (In Russian).
26. Li W, Escarpe PA, Eisinberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, Mendel DB. 1998. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 42: 647-653.
27. McNicholl IR, McNicholl JJ. 2001. Neuraminidase inhibitors: Zanamivir and oseltamivir. Ann Pharmacother 35: 57-70.
28. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, Sweet C, Jakeman KJ, Merson J, Lacy SA, Lew W, Williams MA, Zhang L, Chen MS, Bischofberger N, Kim CU. 1998. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42: 640-646.
29. Merck. 1996. DMSO (entry #3308). In: Budavari S, O'Neil MJ, Smith A, Heckelman PE, Kinneary JF, editors. The Merck Index. An encyclopedia of chemicals, drugs and biologicals. 12th edition. Whitehouse Station, NJ: Merck and Co, Inc.
30. Monto AS, Shope TC, Schwartz SA, Albrecht JK. 1986. Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection. J Infect Dis 154: 128-133.
31. Palmer DF, Dowdle WR, Coleman MT, Schild GC. 1975. Advanced laboratory techniques for influenza diagnosis, Immunology Series 6, Procedural Guide. Atlanta, GA: Center for Disease Control, Public Health Service, US Department of Health and Human Services, pp 25-63.
32. Plotch SJ, O'Hara B, Morin J, Palant O, LaRocque J, Bloom JD, Lang SA Jr, DiGrandi MJ, Bradley M, Nilakantan R, Gluzman Y. 1999. Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J Virol 73: 140-151.
33. Portnoy J, Hicks R, Pacheco F, Olson L. 1988. Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus. Antimicrob Agents Chemother 32: 589-591.
34. Reed LJ, Muench H. 1938. A simple method for estimating 50 per cent endpoints. Am J Hyg 27: 493-497.
35. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubereva LV. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52: 3284-3292.
36. Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, Hou W, Cheng L, Xiao H, Yang Z. 2007. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol 152: 1447-1455.
37. Sidwell RW, Huffman JH, Barnard DL, Bailey KW, Wong MH, Morrison A, Syndergaard T, Kim CU. 1998. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 37: 107-120.
38. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. 1972. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide. Science 177: 705-706.
39. Smee DF, Huffman JH, Morrison AC, Barnard DL, Sidwell RW. 2001. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 45: 743-748.
40. Smee DF, Morrison A, Barnard DL, Sidwell RW. 2002. Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds. J Virol Methods 106: 71-79.
41. Tannock GA, Bryce DA, Paul JA. 1985. Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza virus master strain A/Ann Arbor/6/60-ca Vaccine 3: 333-339.
42. Tannock GA, Gillett SM, Gillett RS, Barry RD, Hensley MJ, Herd R, Reid AL, Saunders NA. 1988. A study of intranasally administered interferon A (rIFN-alpha 2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers. Epidemiol Infect 101: 611-621.
43. Tannock GA, Paul JA, Herd R, Barry RD, Reid AL, Hensley MJ, Gillett RS, Gillett SM, Lawrance P, Henry RL, Saunders NA. 1989. Improved colorimetric assay for detecting influenza B virus neutralizing antibody responses to vaccination and infection. J Clin Microbiol 27: 524-528.
44. Tessier E, Zandomeneghi G, Loquet A, Lavillette D, Lavergne JP, Montserret R, Cosset FL, Böckmann A, Meier BH, Penin F, Pëcheur EI. 2011. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PloS ONE 6: e15874.
45. Tripp RA, Anderson LJ. 1998. Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine. J Virol 72: 8971-8975.
46. Wharton SA, Belshe RB, Skehel JJ, Hay AJ. 1994. Role of virion M2 protein in influenza virus uncoating: Specific reduction in the rate of membrane fusion between virus and liposomes by amantadine. J Gen Virol 75: 945-948.
47. Wiselka MJ, Nicholson KG, Kent J, Cookson JB, Tyrrell DA. 1991. Prophylactic intranasal alpha 2 interferon and viral exacerbations of chronic respiratory disease. Thorax 46: 706-711.